Cargando…
Extended‐Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent form of heart failure, representing half of the total burden of heart failure. We hypothesised that modulation of the phosphodiesterase type 3/cyclic AMP using a novel oral formulation of milrinone might...
Autores principales: | Nanayakkara, Shane, Byrne, Melissa, Mak, Vivian, Carter, Kaye, Dean, Eliza, Kaye, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670502/ https://www.ncbi.nlm.nih.gov/pubmed/32552264 http://dx.doi.org/10.1161/JAHA.119.015026 |
Ejemplares similares
-
Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020) -
Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction
por: Kaye, David M., et al.
Publicado: (2019) -
The Gut Microbiome of Heart Failure With Preserved Ejection Fraction
por: Beale, Anna L., et al.
Publicado: (2021) -
Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction
por: Nanayakkara, Shane, et al.
Publicado: (2018) -
Identification of physiologic treatment targets with favourable haemodynamic consequences in heart failure with preserved ejection fraction
por: Kaye, David M., et al.
Publicado: (2020)